3SBIO

3SBio (1530.HK) surged 5.08% in the morning session, closing at HK$17.78, driven by a combination of news flow and capital inflows. The stock opened at HK$17.02 and quickly climbed to an intraday high of HK$17.78 within 22 minutes, with total volume of 6.715 million shares and turnover of HK$117 million. Despite Orient Securities cutting its stake by 8%, the stock absorbed the selling pressure at the open, buoyed by mainland funds' recent accumulation of Hong Kong-listed biotech names. Financially, Q4 2025 revenue surged 195.52% YoY to HK$7.42 billion, net profit soared 644.38% YoY to HK$3.96 billion, and EPS reached HK$1.5856, reflecting a PE of just 4.79x. However, the stock remains 51.68% below its 52-week high of HK$36.80 and trades below its 60-day moving average of HK$18.498, with a YTD decline of 27.66%, indicating that the medium-term trend has yet to reverse.

3SBIO opened low and rallied in the morning session, trading at HKD 16.960 as of 10:06 BJ time, up 4.89% from the previous close of HKD 16.150, with an intraday low of HKD 16.320 and high of HKD 16.960, on turnover of approximately HKD 127 million and a turnover rate of 0.31%. The stock had been under pressure from dual institutional reductions including Orient Securities' stake cut, but today's buying pushed the price back to reclaim yesterday's losses. Q4 2025 net profit surged 644% YoY to HKD 3.96 billion, with EPS of HKD 1.5856, revenue up 195.5% YoY, net margin of 53.4%, and ROE at 52.4%, reflecting strong fundamentals. However, the stock remains 54% below its 52-week high of HKD 36.80, down 31.1% YTD, and trades below both its MA20 (HKD 17.38) and MA60 (HKD 18.69), suggesting the short-term rebound may face resistance.

SanSheng Pharmaceutical opened sharply lower in the morning session and continued to weaken, trading at HKD 17.02 as of 9:42 BJT, down 4.97%. The stock has now retreated 53.75% from its 52-week high of HKD 36.80 and fallen below its 20-day moving average of HKD 17.39. Despite a low PE of 4.58x and PB of 1.43x, the stock has declined 30.76% year-to-date, reflecting the market's persistently cautious view on its medium-to-long-term growth. However, with a 14.92% upside from the 52-week low of HKD 14.81, some technical oversold rebound potential exists.

1530.HK surged in the morning session, peaking at HK$19.11 (up 9.3% from the intraday low of HK$17.48), but profit-taking emerged in the afternoon, dragging the stock back to close at HK$18.06, still up 3.3% from the open. The rally was fueled by sustained fund buying on drug policy optimism amid a broader sector uptrend. Fundamentals remain robust: Q4 revenue surged 195.5% YoY to HK$7.42 billion, net profit skyrocketed 644.4% YoY to HK$3.96 billion, and EPS came in at HK$1.59. However, the stock closed about 5.5% below the day's high, reflecting heightened short-term volatility and divergent views on valuation.

3SBio opened at HK$17.85 in the morning session of Hong Kong trading but declined sharply to HK$16.94 by 09:45 BJ, down 5.1% from the previous close of HK$17.85, with an intraday range of 5.0%. The stock had rallied recently on drug policy optimism, but today's profit-taking suggests a reversal. Despite strong quarterly results—Q4 2025 operating revenue of HK$7.417 billion (+195.52% YoY), net profit of HK$3.961 billion (+644.38% YoY), and EPS of HK$1.5856—the price remains 53.86% below its 52-week high of HK$36.8, below both MA20 (HK$17.198) and MA60 (HK$19.196), with a YTD decline of 30.92%. However, the stock trades at a low P/B of 1.43x and P/E of 4.57x.